{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:28:09Z","timestamp":1788964089631,"version":"build-2803163510"},"reference-count":43,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Combination therapies in acute myeloid leukemia (AML) are an area of current investigation due to the potential of overcoming resistance by targeting multiple pathways simultaneously. Triplet therapies combining hypomethylating agents, venetoclax, and targeted inhibitors are emerging as a promising therapy for older patients with AML unfit for intensive chemotherapy. These regimens have predominantly been studied in FLT3- and IDH1\/2-mutated AML with attainment of high rates of measurable residual disease-negative composite remissions. Notably, patients with FLT3\u2013internal tandem duplication and IDH1-mutated AML appear to garner a significant benefit from combination treatment due to poor duration of response to hypomethylating agents\/venetoclax alone. While effective, the need to remain on indefinite therapy for individuals who are not stem cell transplant candidates and dose optimization\/de-escalation strategies remain critical concerns. Herein, we aim to review the current treatment landscape of newly diagnosed and relapsed\/refractory FLT3- and IDH1\/2-mutated AML and the role of triplet regimens in these molecular subgroups.<\/jats:p>","DOI":"10.1182\/hematology.2025000754","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:10:07Z","timestamp":1764943807000},"page":"592-598","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Targeted triplet therapies incorporating FLT3 or IDH inhibitors: ready for prime time?"],"prefix":"10.1182","volume":"2025","author":[{"given":"Himachandana","family":"Atluri","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Leukemia Program, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Abaza","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Leukemia Program, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica K.","family":"Altman","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Leukemia Program, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"2025120616350539700_hem2025000754C1","first-page":"46","article-title":"Acute myeloid leukemia management and research in 2025","volume":"75","author":"Kantarjian","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"2025120616350539700_hem2025000754C2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/bjh.19519","article-title":"Combination therapy with novel agents for acute myeloid leukaemia: insights into treatment of a heterogenous disease","volume":"205","author":"Jen","year":"2024","journal-title":"Br J Haematol"},{"key":"2025120616350539700_hem2025000754C3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"2025120616350539700_hem2025000754C4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am J Hematol"},{"key":"2025120616350539700_hem2025000754C5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"2025120616350539700_hem2025000754C6","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"2025120616350539700_hem2025000754C7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"2025120616350539700_hem2025000754C8","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"key":"2025120616350539700_hem2025000754C9","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025120616350539700_hem2025000754C10","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/hematology.2024000540","article-title":"Mutation- and MRD-informed treatments for transplant-ineligible patients","volume":"2024","author":"Lachowiez","year":"2024","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"13","key":"2025120616350539700_hem2025000754C11","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1158\/1078-0432.CCR-21-3405","article-title":"Impact of FLT3 mutation on outcomes after venetoclax and azacitidine for patients with treatment-na\u00efve acute myeloid leukemia","volume":"28","author":"Konopleva","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025120616350539700_hem2025000754C12","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"2025120616350539700_hem2025000754C13","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood.2021014586","article-title":"Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy","volume":"140","author":"Wang","year":"2022","journal-title":"Blood"},{"key":"2025120616350539700_hem2025000754C14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood-2020-134100","article-title":"Results of venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with acute myeloid leukemia with FLT3 mutations","volume":"136","author":"Konopleva","year":"2020","journal-title":"Blood"},{"key":"2025120616350539700_hem2025000754C15","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"issue":"21","key":"2025120616350539700_hem2025000754C16","doi-asserted-by":"crossref","first-page":"5590","DOI":"10.1182\/bloodadvances.2024014017","article-title":"Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy","volume":"8","author":"Othman","year":"2024","journal-title":"Blood Adv"},{"key":"2025120616350539700_hem2025000754C17","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.22.00602","article-title":"Venetoclax plus gilteritinib for FLT3-mutated relapsed\/refractory acute myeloid leukemia","volume":"40","author":"Daver","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025120616350539700_hem2025000754C18","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1200\/JCO.23.01911","article-title":"Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML","volume":"42","author":"Short","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025120616350539700_hem2025000754C19","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1182\/blood-2024-204296","article-title":"Phase I\/II study of quizartinib, venetoclax, and decitabine triple combination in FLT3-ITD mutated AML","volume":"144","author":"Yilmaz","year":"2024","journal-title":"Blood"},{"key":"2025120616350539700_hem2025000754C20","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1182\/blood-2024-210891","article-title":"Long-term survival outcomes and cytogenetic\/molecular patterns of relapse in adults with FLT3-mutated AML receiving frontline triplet therapy with a hypomethylating agent, venetoclax and FLT3 inhibitor","volume":"144","author":"Short","year":"2024","journal-title":"Blood"},{"key":"2025120616350539700_hem2025000754C21","doi-asserted-by":"crossref","first-page":"2907.2901","DOI":"10.1182\/blood-2024-199701","article-title":"A randomized phase II study of venetoclax and HMA-based therapies for the treatment of older and unfit adults with newly diagnosed FLT3-mutated acute myeloid leukemia (AML): a myelomatch treatment trial: ECOG-ACRIN MM20A-EA02","volume":"144","author":"Altman","year":"2024","journal-title":"Blood"},{"issue":"19","key":"2025120616350539700_hem2025000754C22","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood.2024025154","article-title":"Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD- mutated AML","volume":"145","author":"Levis","year":"2025","journal-title":"Blood"},{"key":"2025120616350539700_hem2025000754C23","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025120616350539700_hem2025000754C24","doi-asserted-by":"crossref","first-page":"S271","DOI":"10.1016\/S2152-2650(23)00999-0","article-title":"AML-112: impact of consolidation chemotherapy intensity before allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia","volume":"23","author":"Bardol","year":"2023","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"2025120616350539700_hem2025000754C25","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/hematology.2019000006","article-title":"Minimal residual disease and stem cell transplantation outcomes","volume":"2019","author":"Cloos","year":"2019","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2025120616350539700_hem2025000754C26","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood.2023023096","article-title":"Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"key":"2025120616350539700_hem2025000754C27","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","article-title":"Impact of venetoclax and azacitidine in treatment-na\u00efve patients with acute myeloid leukemia and IDH1\/2 mutations","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025120616350539700_hem2025000754C28","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"2025120616350539700_hem2025000754C29","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2025120616350539700_hem2025000754C30","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2352-3026(22)00292-7","article-title":"Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1\/2 trial","volume":"10","author":"Watts","year":"2023","journal-title":"Lancet Haematol"},{"issue":"21","key":"2025120616350539700_hem2025000754C31","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"key":"2025120616350539700_hem2025000754C32","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"key":"2025120616350539700_hem2025000754C33","doi-asserted-by":"crossref","first-page":"7012","DOI":"10.1200\/JCO.2023.41.16_suppl.7012","article-title":"Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine","volume":"41","author":"Botton","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025120616350539700_hem2025000754C34","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41408-023-00915-6","article-title":"Response patterns and impact of MRD in patients with IDH1\/2-mutated AML treated with venetoclax and hypomethylating agents","volume":"13","author":"Hammond","year":"2023","journal-title":"Blood Cancer J"},{"key":"2025120616350539700_hem2025000754C35","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2023-187060","article-title":"I-DATA study: randomized, sequential, open-label study to evaluate the efficacy of IDH targeted\/ non-targeted versus non-targeted\/IDH-targeted approaches in the treatment of newly diagnosed IDH mutated adult AML patients not candidates for intensive induction therapy","volume":"142","author":"Ozga","year":"2023","journal-title":"Blood"},{"key":"2025120616350539700_hem2025000754C36","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S1470-2045(21)00494-0","article-title":"Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial","volume":"22","author":"DiNardo","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025120616350539700_hem2025000754C37","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1182\/blood-2023-182944","article-title":"Phase Ib\/2 study of oral decitabine\/ cedazuridine (ASTX727) and venetoclax in combination with the targeted mutant IDH1 inhibitor ivosidenib or the targeted mutant IDH2 inhibitor enasidenib: 2023 update","volume":"142","author":"Atluri","year":"2023","journal-title":"Blood"},{"key":"2025120616350539700_hem2025000754C38","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1182\/blood-2024-200387","article-title":"Clinical outcomes using frontline \u201ctriplet\u201d regimens for newly diagnosed IDH-mutated acute myeloid leukemia (AML): a pooled analysis of two phase Ib\/2 clinical trials","volume":"144","author":"Marvin-Peek","year":"2024","journal-title":"Blood"},{"issue":"24","key":"2025120616350539700_hem2025000754C39","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO-25-00640","article-title":"Outcomes of frontline triplet regimens with a hypomethylating agent, venetoclax, and isocitrate dehydrogenase inhibitor for intensive chemotherapy-ineligible patients with isocitrate dehydrogenase-mutated AML","volume":"43","author":"DiNardo","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025120616350539700_hem2025000754C40","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/2643-3230.BCD-22-0205","article-title":"A phase Ib\/II study of ivosidenib with venetoclax\u200a\u00b1\u200aazacitidine in IDH1-mutated myeloid malignancies","volume":"4","author":"Lachowiez","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"2025120616350539700_hem2025000754C41","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2024-200393","article-title":"A phase Ib\/II study of ivosidenib with venetoclax\u00b1azacitidine in IDH1-mutated hematologic malignancies: a 2024 update","volume":"144","author":"Marvin-Peek","year":"2024","journal-title":"Blood"},{"key":"2025120616350539700_hem2025000754C42","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1200\/JCO.2020.38.15_suppl.7501","article-title":"Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 newly diagnosed acute myeloid leukemia (ND-AML)","volume":"38","author":"Dinardo","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025120616350539700_hem2025000754C43","article-title":"Phase I\/II study of decitabine\/cedazuridine (ASTX727), venetoclax, and gilteritinib for patients with FLT3-mutated acute myeloid leukemia or high-risk myelodysplastic syndrome","author":"Azevedo","year":"2025"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/592\/2469816\/592atluri.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/592\/2469816\/592atluri.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:35:16Z","timestamp":1765056916000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2025\/1\/592\/556906\/Targeted-triplet-therapies-incorporating-FLT3-or"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2025000754","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,5]]},"published":{"date-parts":[[2025,12,5]]}}}